Switch to: References

Add citations

You must login to add citations.
  1. A Fictionalist Account of Open-Label Placebo.Doug Hardman - 2024 - Journal of Medicine and Philosophy 49 (3):246-256.
    The placebo effect is now generally defined widely as an individual’s response to the psychosocial context of a clinical treatment, as distinct from the treatment’s characteristic physiological effects. Some researchers, however, argue that such a wide definition leads to confusion and misleading implications. In response, they propose a narrow definition restricted to the therapeutic effects of deliberate placebo treatments. Within the framework of modern medicine, such a scope currently leaves one viable placebo treatment paradigm: the non-deceptive and non-concealed administration of (...)
    Download  
     
    Export citation  
     
    Bookmark   1 citation  
  • Meaning and Affect in the Placebo Effect.Daniele Chiffi, Ahti-Veikko Pietarinen & Alessandro Grecucci - 2021 - Journal of Medicine and Philosophy 46 (3):313-329.
    This article presents and defends an integrated view of the placebo effect, termed “affective-meaning-making” model, which draws from theoretical reflection, clinical outcomes, and neurophysiological findings. We consider the theoretical limitations of those proposals associated with the “meaning view” on the placebo effect which leave the general aspects of meaning unspecified, fail to analyze fully the role of emotions and affect, and establish no clear connection between the theoretical, physiological, and psychological aspects of the effect. We point out that a promising (...)
    Download  
     
    Export citation  
     
    Bookmark   2 citations  
  • Overcoming disagreement: a roadmap for placebo studies.Charlotte Blease & Marco Annoni - 2019 - Biology and Philosophy 34 (2):18.
    In the field of placebo studies residual disagreement about the terminology ‘placebo’ and ‘placebo effect’ still persists. We differentiate between the conceptualization of placebos in clinical trials; and placebo effects understood as a psychobiological phenomenon. With respect to the latter, we argue that a scientific ‘placebo paradigm’ has emerged, indicating that—at least among placebo scientists—there exists relatively stable consensus about how to conceive of placebo effects. We claim that existence of a placebo paradigm does not protect concepts from revision; nonetheless, (...)
    Download  
     
    Export citation  
     
    Bookmark   4 citations  
  • Is there a nocebo response that results from disease awareness campaigns and advertising in Australia, and can this effect be mitigated?Stuart Benson & David Hunter - 2018 - Journal of Medical Ethics 44 (9):621-625.
    Direct-to-consumer advertising is banned in Australia, and instead pharmaceutical companies use disease awareness campaigns as a strategy to raise public awareness of conditions for which the company produces a treatment. This practice has been justified by promoting individual autonomy and public health, but it has attracted criticism regarding medicalisation of normal health and ageing, and exaggeration of the severity of the condition in question, imbalanced reporting of risks and benefits, and damaging the patient–clinician relationship. While there are benefits of disease (...)
    Download  
     
    Export citation  
     
    Bookmark   1 citation  
  • The placebo phenomenon and medical ethics: Rethinking the relationship between informed consent and risk–benefit assessment.Franklin G. Miller & Luana Colloca - 2011 - Theoretical Medicine and Bioethics 32 (4):229-243.
    It has been presumed within bioethics that the benefits and risks of treatments can be assessed independently of information disclosure to patients as part of the informed consent process. Research on placebo and nocebo effects indicates that this is not true for symptomatic treatments. The benefits and risks that patients experience from symptomatic treatments can be shaped powerfully by information about these treatments provided by clinicians. In this paper we discuss the implications of placebo and nocebo research for risk–benefit assessment (...)
    Download  
     
    Export citation  
     
    Bookmark   19 citations